Researchers: Yali Zhang, Yufeng He, Siqi Liu, Li Deng, Yumei Zuo, Keming Huang, Bin Liao, Guang Li, Jian Feng
Population aging combined with higher susceptibility to cardiovascular diseases in older adults is increasing the incidence of conditions such as atherosclerosis, myocardial infarction, heart failure, myocardial hypertrophy, myocardial fibrosis, arrhythmia, and hypertension. sodium-glucose cotransporter 2 inhibitors (SGLT2i) were originally developed as a novel oral drug for patients with type 2 diabetes mellitus. Unexpectedly, recent studies have shown that, beyond their effect on hyperglycemia, SGLT2i also have a variety of beneficial effects on cardiovascular disease. Experimental models of cardiovascular disease have shown that SGLT2i ameliorate the process of aging-related cardiovascular disease by inhibiting inflammation, reducing oxidative stress, and reversing endothelial dysfunction. In this review, we discuss the role of SGLT2i in aging-related cardiovascular disease and propose the use of SGLT2i to prevent and treat these conditions in older adults.
References
- Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease.
- The hallmarks of aging.
- Aging: Molecular Pathways and Implications on the Cardiovascular System.
- The intersection between aging and cardiovascular disease.
- Age-associated proinflammatory secretory phenotype in vascular smooth muscle cells from the non-human primate Macaca mulatta: reversal by resveratrol treatment.
- Gut microbiome and aging: Physiological and mechanistic insights.
Topic: Transportation for elderly